Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1)

NCT02059135 is registered in ClinicalTrials.gov with rEVO Biologics as lead sponsor.

NCT NCT02059135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02059135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1)
Lead sponsor
rEVO Biologics
Phase
Phase 3
Overall status
Completed
Start date
July 11, 2014
Completion date
November 30, 2016
Enrollment
120 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

preeclampsia